Analysts Raise EPS Estimates and Target Prices for uniQure N.V.

Summary

Equities research analysts at William Blair have raised their Q3 2026 EPS estimates for uniQure N.V. to ($0.29) from ($0.55). The consensus estimate for the full-year earnings is ($3.75) per share. Analysts from Chardan Capital, Cantor Fitzgerald, Wells Fargo, Stifel Nicolaus, and Leerink Partners have also increased their target prices for uniQure shares, with an average target of $67.17. The company reported ($0.69) EPS for the last quarter, beating estimates, and has a market cap of $2.98 billion. Insider selling has been noted, with significant shares sold by CFO and CEO.Market Beat

Impact Analysis

So basically, analysts are quite optimistic about uniQure’s future, especially after the positive trial results for its Huntington’s disease gene therapy, which sent the stock soaring by 248% recently Benzinga+ 2. The raised EPS estimates and target prices suggest strong confidence in the company’s growth trajectory Market Beat. However, the insider selling by the CFO and CEO is a bit of a red flag—it could indicate that management might not be as confident as the analysts are Market Beat. The market seems focused on the potential upside from the gene therapy, but the insider activity could dampen sentiment if investors start questioning the long-term viability. I’d read this as a mixed signal: while the stock has momentum, the insider selling could be a cautionary tale. Watching how the stock reacts to these mixed signals could reveal more about market sentiment and potential entry points.